1Zaffran Y, Meyer SC, Negrescu E, et al. Signaling across the platelet adhesion receptor glycoprotein Ib-IX induces α Ⅱ bβ3 actuvation both in platelets and a transfected Chinese hamster ovary cell system[ J]. J Biol Chem, 2000,275 ( 22 ) : 16779 -16787.
3Calvete JJ. Structures of integrin domains and concerted conformational changes in the bidirectional signaling mechanism of alphaIIbbeta3 [J]. Exp Biol Med,2004,229(8) :732-744.
4Kappelmayer J,Nagy B Jr,Miszti-Blasius K,et al. The emerging value of P-selectin as a disease marker[J]. Clim Chem Lab Med,2004,42 (5) :475.486.
6Andrioli G, Ortolani R, Fontana L, et al. Study of platelet adhesion in patients with uncomplicated hypertension [ J ]. J Hypertens, 1996,14 (10) : 1215-1221.
7Celik T, Yuksel UC, Iyisoy A, et al. Effects of nebivolol on platelet activation in hypertensive patients:a comparative study with metoprolol [J]. Int J Cardiol,2007,116(2) :206-211.
8Blaha V, Andrys C,Smahelova A, et al. Effect of atorvastatin on soluble CD14, CIMO Ligand, sE-and sP-selectins and MCP-1 in patients with type 2 diabetes mellitus: relationship to cholesterol turnover[ J]. Pharmacol Res,2006,54 ( 6 ) :421-428.
9Parise P, Hauert J, Iorio A, et al. Streptokinase and rt-PA activate platelets by a different way:Implications on the rethrombosis rate after their administration in myocardial infarction [ J ]. J Lab Clin Med, 1995,125 (2) :212-221.
10Gurbel PA, Serebruany VL, Shustov AR, et al. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-Ⅲ Investigators. Global use of strategies to open occluded coronary arteries[J]. J Am Coll Cardiol,1998,31 (7) :1466-1473.
2Belniak-Legiec E, Stelmasiak Z. Blood platelet activation markers in patients with acute cerebral infarction during the earliest stage of the disease-evaluation using flow cytometry methods [ J ]. Neurol Neurochir Pol, 2000,34(5) :853-864.
3Karepov VG, Gur AY, Bova I, et al. Stroke-in-evolution: infarct- inherent mechanisms versus systemic causes [ J ]. Cerebrovasc Dis, 2006,21 ( 1-2 ) :42-46.
4Blann AD, Lip GY. Hypothesis: is soluble P-selectin a new marker of platelet activation [J]. Atherosclerosis, 1997,128 (2) : 135-138.
5O' Rourke F, Dean N, Akhtar N, et al. Current and future concepts in stroke prevention [J]. CMAJ, 2004,170(7):1123-1133.
6Belniak-Legie E,Stelmasiak Z.Blood platelet activation markers in patients with acute cerebral infarction during the earliest stage of the disease--evaluation using flow cytometry methods[J].Neurol Neurochir Pol,2000,34(5):853-864.
7Karepov VG,Gur AY,Bova I,et al.Stroke-in-evolution:infarctinherent mechanisms versus systemic causes[J].Cerebrovasc Dis,2006,21(1-2):42-46.
8Blann AD,Lip GY.Hypothesis:is soluble P-selectin a new marker of platelet activation[J].Atherosclerosis,1997,128(2):135-138.
9O'Rourke F,Dean N,Akhtar N,et al.Current and future concepts in stroke prevention[J].CMAJ,2004,170(7):1123-1133.
